CX3CL1 and COVID-19: Remarkably, patients with severe COVID-19 maintained significantly higher systemic IP-10, IL-1RA, IL-10, IL-15, and MIP-1β levels and mucosal IL-1RA, IL-12p40, and fractalkine through recovery and convalescence (Fig. S6A and B).